What Happened to Disc Medicine?

Disc Medicine became publicly traded through a reverse merger with Gemini Therapeutics in 2022. Gemini had originally gone public via a SPAC merger with FS Development Corp (sponsored by Foresite Capital) in February 2021. After Gemini's drug candidates failed, Disc Medicine used the reverse merger to gain a public listing for its hematology pipeline, which includes treatments for erythropoietic porphyria and other rare blood disorders. The stock has performed well on clinical trial progress.